The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1686
ISSUE1686
Med Lett Drugs Ther. 2023 Oct 2;65(1686):160 doi:10.58347/tml.2023.1686f
Disclosures
Objective(s)
Since the publication of our articles entitled Drugs for Opioid Use Disorder and In Brief: Over-the-Counter Narcan Nasal Spray earlier this year, Narcan (Emergent), a nasal spray that delivers 4 mg of the opioid antagonist naloxone, has become available for sale over the counter (OTC). According to the manufacturer, the retail price for a box containing 2 doses is $44.99. Some insurance companies have announced plans to cover OTC purchase of the drug for their members.
RiVive (Harm Reduction Therapeutics), a 3-mg naloxone nasal spray recently FDA-approved for OTC sale, is expected to be marketed early next year.
© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and
complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any
damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
Previous article